Dermata is a pre-revenue skincare company pivoting from prescription drug development to consumer skincare under its new brand, Tome. Dermata's core technology is Bioneedle, a powder derived from Spongilla lacustris, a freshwater sponge. The Bioneedle works mechanically — microscopic silica spicules physically penetrate the skin to create microchannels — and organically, via bioactive antimicrobial and anti-inflammatory compounds in the sponge. Dermata's first two products are expected to launch in 2026: the Tome Foundational Treatment, a once-weekly skin renewal kit, and the Tome Clearing Treatment, an acne-focused system combining weekly Bioneedle treatments with daily salicylic acid wipes. Both are sold as monthly kits with subscription options. Dermata sells DTC through its own website and B2B to aestheticians, med spas, and dermatology practices. The B2B channel will include a paid certification program for skincare professionals. The revenue model is built around recurring purchases, with key drivers being customer acquisition cost, subscription attach rates, and repeat purchase frequency. Dermata does not manufacture its own products, relying on third-party contract manufacturers and a single Russian supplier, Reka-Farm, for its Spongilla raw material. Dermata's growth strategy centers on expanding the Bioneedle platform across additional skin conditions, building a professional certification network, and pursuing M&A to broaden the Tome portfolio.